Insilico opens representative office in Singapore to expand business in Asia
Stuttgart – Insilico Biotechnology AG announces the opening of a representation in Singapore to develop its business in the Asia-Pacific (APAC) region and to strengthen support for its growing customer base.
The biopharmaceutical market in Asia is doubling every six years with sharply rising demand for high-quality and cost-effective drugs. Insilico sees great business opportunities for the use of its predictive Digital Twins for next generation bioprocess development to meet these market demands. Digital Twins are a central element of digital facilities as they enable virtual experimentation as well as model-predictive control of bioprocesses.
Developing a global footprint is a high priority for the Stuttgart-based company in the coming years, which includes strong expansion of their customer base in Asia. Moreover, Insilico Biotechnology plans to attract data scientists in APAC for exciting roles at the intersection of data science and biotechnology.
Klaus Mauch, CEO of Insilico, emphasizes that "opening a representative office at the heart of APAC now is a great opportunity for Insilico Biotechnology. Singapore is not only a great location geographically, but also a major biopharmaceuticals manufacturing hub of APAC." Insilico’s newly appointed chief representative, Dr. Shilpa Nargund adds "Singapore is well known for its business-friendly administration that strongly encourages high-tech companies. I am happy to be a part of Insilico’s representation here and am looking forward to developing our business in APAC."
Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Groundbreaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilico's unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany. Learn more at www.insilico-biotechnology.com
Insilico Biotechnology AG
Dr. Daniel Horbelt | Business Development
T +49 711 460 594-14
F +49 711 460 594-10